DRUG INTERACTIONS: Drug interaction studies have not been conducted with omalizumab.
PREGNANCY: Omalizumab has not been adequately studied in pregnant women.
NURSING MOTHERS: Use of omalizumab by nursing mothers has not been adequately evaluated. Since antibodies similar to omalizumab are excreted in human breast milk, it is likely that omalizumab also is excreted in breast milk.
SIDE EFFECTS: The most common side effects observed in patients treated with omalizumab are headaches, viral infections, upper respiratory tract infections, and injection-site reactions such as pain, redness, swelling, itching and bruising. Use of omalizumab may also lead to serious, life-threatening allergic reactions (anaphylaxis) which manifest as bronchospasm with difficulty breathing, fainting, low blood pressure, and swelling of the tongue or throat. It is recommended that patients be observed for these reactions for at least two hours after injection of omalizumab; however, these reactions can occur up to 24 hours or longer after the injections, and they have occurred even after one year of regular treatment. Since allergic reactions can occur after any dose, patients should carry medications for emergency self-treatment. In clinical trials cancer occurred more frequently in patients who took omalizumab.
Reference: FDA Prescribing Information
Quick GuideAsthma Pictures Slideshow: An Inflammatory Disorder of the Airways
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.